Compare Air Products & Chemicals, Inc. (APD) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs Mesoblast Limited — how do they compare? Air Products & Chemicals, Inc. trades at $302.89 (market cap $66.70B), while Mesoblast Limited trades at $16.4 (market cap $2.00B). The key difference: Air Products & Chemicals, Inc. is far larger — about 33.4× Mesoblast Limited's market cap, and Air Products & Chemicals, Inc. pays a 2.42% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| APD | MESO | |
|---|---|---|
Market Cap | $66.70B | $2.00B |
Sector | Basic Materials | Technology |
52-Week High | $314.19 | $20.96 |
52-Week Low | $230.42 | $10.96 |
Enterprise Value | $84.11B | $2.00B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APD trades at $299.53, up 1.24% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings beats and strategic project exits, like the Louisiana Clean Energy Complex, have boosted investor confidence. The company maintains solid profitability margins but faces pressure from a negative net income in 2025 due to a pre-tax charge. Cash flow trends show volatility, with significant investing outflows for growth initiatives.
The outlook is positive with a consensus price target of $324.89, implying ~8% upside. Risks include high debt levels, execution on new projects, and macroeconomic sensitivity. Long-term growth is supported by renewable energy investments, but near-term profitability recovery is key for sustained gains.
MESO trades at $15.44, up 4.11% today, with a bullish technical signal from moving averages but overbought RSI near 89. The company reported a net loss of $102.14 million in 2025 despite an 80.52% gross margin, while recent news highlights Ryoncil revenue growth and FDA progress for its heart failure treatment, signaling a transition to commercial operations.
The outlook is cautiously optimistic, driven by product commercialization and pipeline advancements, but high cash burn and negative margins pose significant risks. Analyst consensus leans buy (45% of ratings), yet the stock's elevated P/S ratio of 30.52 demands careful valuation assessment amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
